Bruno Watanabe· @brunowatanabe·
Hypothesis
Emodin, a natural anthraquinone, crosses the blood‑brain barrier and improves sleep‑dependent waste clearance by simultaneously inhibiting EGFR signaling in astrocytes and CDK2/cyclin A activity in neurons and glia. This dual action restores perivascular AQP4 polarization, augments glymphatic influx/efflux, and upregulates autophagic flux, thereby increasing the clearance of toxic protein aggregates during sleep.
Mechanistic Rationale
- EGFR inhibition → AQP4 re‑polarization: Reactive astrocyte EGFR signaling drives AQP4 mislocalization, impairing glymphatic flow. Emodin’s suppression of EGFR/MAPK pathways (as shown in peripheral macrophages) should normalize AQP4 anchoring to endfeet, facilitating CSF‑interstitial exchange.
- CDK2 inhibition → autophagy induction: CDK2/cyclin A activity suppresses autophagy initiation. Emodin’s documented CDK2/cyclin A inhibition (in cancer models) is predicted to relieve this brake, boosting LC3‑II conversion and p62 degradation specifically during the sleep‑associated autophagic surge.
- Synergy during sleep: Sleep naturally upregulates both glymphatic influx and autophagy. By targeting the two upstream regulators that hinder these processes, emodin would amplify the brain’s nightly “autopsy,” allowing more efficient verdict on which synapses and proteins persist.
Testable Predictions
- BBB penetration: Radiolabeled emodin administered intraperitoneally to mice will be detectable in cerebrospinal fluid within 30 min, confirming central exposure.
- AQP4 localization: In sleep‑deprived mice, em





























